Stockreport

Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress [Yahoo! Finance]

Revolution Medicines, Inc.  (RVMD) 
PDF Net Loss : Net loss widened to $161.5 million in Q4 2023 from $56.5 million in Q4 2022. Cash Position : Cash, cash equivalents, and marketable securities stood at $1. [Read more]